Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed
暂无分享,去创建一个
[1] B. Yankner,et al. Amyloid Fibril Toxicity in Alzheimer's Disease and Diabetes a , 1996, Annals of the New York Academy of Sciences.
[2] J. Born,et al. Intranasal Insulin to Improve Memory Function in Humans , 2007, Neuroendocrinology.
[3] S. M. de la Monte,et al. Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. , 2008, Journal of Alzheimer's disease : JAD.
[4] S. Hoyer,et al. Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats , 1994, International Journal of Developmental Neuroscience.
[5] R. Martins,et al. Insulin Effects on Glucose Metabolism, Memory, and Plasma Amyloid Precursor Protein in Alzheimer's Disease Differ According to Apolipoprotein‐E Genotype , 2000, Annals of the New York Academy of Sciences.
[6] Sanjay Asthana,et al. Insulin dose–response effects on memory and plasma amyloid precursor protein in Alzheimer’s disease: interactions with apolipoprotein E genotype , 2003, Psychoneuroendocrinology.
[7] H. Braak,et al. Assessment of the Pathological Stages of Alzheimer’s Disease in Thin Paraffin Sections: A Comparative Study , 1998, Dementia and Geriatric Cognitive Disorders.
[8] G. Landreth. Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. , 2007, Current Alzheimer research.
[9] A. Nitta,et al. Diabetic neuropathies in brain are induced by deficiency of BDNF. , 2002, Neurotoxicology and teratology.
[10] A. Klippel,et al. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt , 1997, Molecular and cellular biology.
[11] P. Damm,et al. Lower levels of circulating IGF‐I in Type 1 diabetic women with frequent severe hypoglycaemia during pregnancy , 2008, Diabetic medicine : a journal of the British Diabetic Association.
[12] M. White,et al. The IRS-1 signaling system. , 1994, Trends in biochemical sciences.
[13] I. Mavromichalis,et al. Update on non-alcoholic fatty liver disease in children. , 2007, Clinical nutrition.
[14] M. Haan. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease , 2006, Nature Clinical Practice Neurology.
[15] I. Nishimoto,et al. Death and survival of neuronal cells exposed to Alzheimer's insults , 2002, Journal of neuroscience research.
[16] H. Braak,et al. Diagnostic Criteria for Neuropathologic Assessment of Alzheimer’s Disease , 1997, Neurobiology of Aging.
[17] Xiao-Ping Wang,et al. Alzheimer’s disease: epidemiology, genetics, and beyond , 2008, Neuroscience bulletin.
[18] R. Quirion,et al. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. , 2002, Progress in neurobiology.
[19] M. Reger,et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[20] G. Landreth. PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease. , 2006, Experimental neurology.
[21] S. Hoyer,et al. Inhibition of the Neuronal Insulin Receptor An in Vivo Model for Sporadic Alzheimer Disease? , 2000, Annals of the New York Academy of Sciences.
[22] J. Born,et al. Intranasal Insulin Improves Memory in Humans: Superiority of Insulin Aspart , 2007, Neuropsychopharmacology.
[23] M. Haan,et al. Can dementia be prevented? Brain aging in a population-based context. , 2004, Annual review of public health.
[24] S. Hoyer,et al. Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus , 1993, International Journal of Developmental Neuroscience.
[25] Gunhild Waldemar,et al. Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[26] K. Jellinger,et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease , 1998, Journal of Neural Transmission.
[27] P. Riederer,et al. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein , 2007, Journal of neurochemistry.
[28] C. Duyckaerts,et al. Impaired brain development and hydrocephalus in a line of transgenic mice with liver-specific expression of human insulin-like growth factor binding protein-1. , 2000, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[29] M. Weinstock,et al. Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity , 2004, Journal of Neural Transmission.
[30] K. Jellinger,et al. Synaptic Pathology of Alzheimer's Disease a , 1993, Annals of the New York Academy of Sciences.
[31] M. White,et al. Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1 , 1993, Molecular and cellular biology.
[32] P. Eikelenboom,et al. Neuroinflammatory perspectives on the two faces of Alzheimer’s disease , 2004, Journal of Neural Transmission.
[33] S. Hoyer,et al. Inhibition of the Neuronal Insulin Receptor Causes Alzheimer‐like Disturbances in Oxidative/Energy Brain Metabolism and in Behavior in Adult Rats , 1999, Annals of the New York Academy of Sciences.
[34] B. Hyman,et al. Cerebrovascular Pathology Contributes to the Heterogeneity of Alzheimer's Disease. , 1998, Journal of Alzheimer's disease : JAD.
[35] S. Hoyer. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. , 2004, European journal of pharmacology.
[36] G. Landreth. PPARγ agonists as new therapeutic agents for the treatment of Alzheimer's disease , 2006, Experimental Neurology.
[37] M. Nicolls,et al. The clinical and biological relationship between Type II diabetes mellitus and Alzheimer's disease. , 2004, Current Alzheimer research.
[38] C. Álvarez,et al. Defective IGF2 and IGF1R protein production in embryonic pancreas precedes beta cell mass anomaly in the Goto–Kakizaki rat model of type 2 diabetes , 2007, Diabetologia.
[39] S. Craft,et al. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice , 2006, Experimental Neurology.
[40] N. Brown,et al. Partial rescue of ethanol-induced neuronal apoptosis by growth factor activation of phosphoinositol-3-kinase. , 2000, Alcoholism, clinical and experimental research.
[41] G. Winocur,et al. Studies of the effects of high fat diets on cognitive function in a rat model , 2005, Neurobiology of Aging.
[42] R. Quirion,et al. Alzheimer’s disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies , 2002, Progress in Neurobiology.
[43] Yamamura Ken-ichi,et al. Expression of the gene encoding the tyrosine kinase-deficient human insulin receptor in transgenic mice. , 1994 .
[44] S. Hoyer. Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. , 2004, Advances in experimental medicine and biology.
[45] J. Sykes,et al. Development of oligodendrocytes. Studies of rat glial cells cultured in chemically-defined medium. , 1989, Journal of developmental physiology.
[46] K. Eguchi,et al. Recent Advancement of Understanding Pathogenesis of Type 1 Diabetes and Potential Relevance to Diabetic Nephropathy , 2007, American Journal of Nephrology.
[47] P. Scheltens,et al. Brain Aging in Very Old Men With Type 2 Diabetes , 2006, Diabetes Care.
[48] Mark A. Smith,et al. 4‐Hydroxynonenal‐Derived Advanced Lipid Peroxidation End Products Are Increased in Alzheimer's Disease , 1997, Journal of neurochemistry.
[49] S. Hoyer,et al. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. , 1998, Behavioral neuroscience.
[50] J. Wands,et al. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.
[51] J. Wands,et al. Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease , 1997, Journal of the Neurological Sciences.
[52] J. Wands,et al. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. , 2005, Journal of Alzheimer's disease : JAD.
[53] H. Arias,et al. The role of inflammation in Alzheimer's disease. , 2005, The international journal of biochemistry & cell biology.
[54] N. Ruderman,et al. The phosphatidylinositol 3-kinase serine kinase phosphorylates IRS-1. Stimulation by insulin and inhibition by Wortmannin. , 1994, The Journal of biological chemistry.
[55] G. Schellenberg,et al. Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype , 2006, Neurobiology of Aging.
[56] P. Pilch,et al. Intrinsic kinase activity of the insulin receptor. , 1990, The International journal of biochemistry.
[57] O. Felician,et al. The neurobiology and pharmacotherapy of Alzheimer's disease. , 1999, The Journal of neuropsychiatry and clinical neurosciences.
[58] W. Meier-Ruge,et al. Glycolytic enzymes from human autoptic brain cortex: Normal aged and demented cases , 1980, Mechanisms of Ageing and Development.
[59] P. Riederer,et al. Alzheimer‐like changes in protein kinase B and glycogen synthase kinase‐3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway , 2006, Journal of neurochemistry.
[60] Laura Fratiglioni,et al. The epidemiology of the dementias: an update , 2007, Current opinion in psychiatry.
[61] K. Jellinger. Neuropathological Aspects of Alzheimer Disease, Parkinson Disease and Frontotemporal Dementia , 2008, Neurodegenerative Diseases.
[62] J. Wands,et al. Chronic gestational exposure to ethanol causes insulin and IGF resistance and impairs acetylcholine homeostasis in the brain , 2006, Cellular and Molecular Life Sciences CMLS.
[63] J. Wands,et al. Ethanol impairs insulin-stimulated mitochondrial function in cerebellar granule neurons , 2001, Cellular and Molecular Life Sciences CMLS.
[64] Mark A. Reger,et al. Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease , 2006, Neurobiology of Aging.
[65] A. Bolzán,et al. Genotoxicity of streptozotocin. , 2002, Mutation research.
[66] K. Lapane,et al. Dementia of the Alzheimer type. , 2008, Epidemiologic reviews.
[67] P. Cicconetti,et al. Fattori di rischio per il decadimento cognitivo , 2004 .
[68] J. Kushner,et al. Insulin Receptor Substrate-2 Deficiency Impairs Brain Growth and Promotes Tau Phosphorylation , 2003, The Journal of Neuroscience.
[69] D. Neary,et al. GLUCOSE METABOLISM AND ACETYLCHOLINE SYNTHESIS IN RELATION TO NEURONAL ACTIVITY IN ALZHEIMER'S DISEASE , 1980, The Lancet.
[70] V. Lee,et al. Insulin and Insulin-like Growth Factor-1 Regulate Tau Phosphorylation in Cultured Human Neurons* , 1997, The Journal of Biological Chemistry.
[71] P. Riederer,et al. Reduced Brain Antioxidant Capacity in Rat Models of Betacytotoxic-Induced Experimental Sporadic Alzheimer’s Disease and Diabetes Mellitus , 2007, Neurochemical Research.
[72] Christos Tiniakos. Pathology of nonalcoholic fatty liver disease , 2007 .
[73] C. Kahn,et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein , 1991, Nature.
[74] D. Selkoe,et al. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. , 2004, The American journal of pathology.
[75] S. Craft. Insulin Resistance Syndrome and Alzheimer Disease: Pathophysiologic Mechanisms and Therapeutic Implications , 2006, Alzheimer disease and associated disorders.
[76] P. Mehta,et al. Intranasal insulin improves cognition and modulates β-amyloid in early AD , 2008, Neurology.
[77] M. Biju,et al. Brain glutamate dehydrogenase changes in streptozotocin diabetic rats as a function of age , 1998, Biochemistry and molecular biology international.
[78] C. Kahn,et al. Insulin rapidly stimulates tyrosine phosphorylation of a Mr-185,000 protein in intact cells , 1985, Nature.
[79] J. Wands,et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. , 2005, Journal of Alzheimer's disease : JAD.
[80] M. Chao,et al. Insulin, insulin-like growth factor II, and nerve growth factor effects on tubulin mRNA levels and neurite formation. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[81] D L Price,et al. New perspectives on Alzheimer's disease. , 1986, Annual review of neuroscience.
[82] B. Winblad,et al. The Effect of Borderline Diabetes on the Risk of Dementia and Alzheimer’s Disease , 2007, Diabetes.
[83] S. M. de la Monte,et al. Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection. , 2003, Journal of Alzheimer's disease : JAD.
[84] J. Wands,et al. Ethanol Impairs Insulin-stimulated Neuronal Survival in the Developing Brain , 2003, Journal of Biological Chemistry.
[85] P. H. Seeburg,et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes , 1985, Nature.
[86] A. Brun,et al. Cortical synaptic changes and gliosis in normal aging, Alzheimer's disease and frontal lobe degeneration. , 1996, Dementia.
[87] R. Whitmer. Type 2 diabetes and risk of cognitive impairment and dementia , 2007, Current neurology and neuroscience reports.
[88] S. M. de la Monte,et al. Quantitation of cerebral atrophy in preclinical and end‐stage alzheimer's disease , 1989, Annals of neurology.
[89] C. Kahn,et al. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. , 1999, The Journal of clinical investigation.
[90] R. Veerhuis,et al. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes , 2004, Aging cell.
[91] David R. Kaplan,et al. Regulation of Neuronal Survival by the Serine-Threonine Protein Kinase Akt , 1997, Science.
[92] Impaired insulin signaling and the pathogenesis of Alzheimer's disease. , 2006, Drugs of today.
[93] G. Farrell. Non‐Alcoholic Fatty Liver and Non‐Alcoholic Steatohepatitis , 2008 .
[94] R. Mayeux,et al. Cardiovascular risk factors and Alzheimer’s disease , 2004, Current atherosclerosis reports.
[95] G. Landreth. Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. , 2007, Current Alzheimer research.
[96] H. Fibiger,et al. Chapter 49: Role of forebrain cholinergic systems in learning and memory: relevance to the cognitive deficits of aging and Alzheimer's dementia , 1993 .
[97] S. Hoyer,et al. Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism. , 1994, Journal of neural transmission. Supplementum.
[98] P. Moreira,et al. Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes , 2007, Journal of the Neurological Sciences.
[99] R. Martins,et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease , 2006, Molecular Psychiatry.
[100] M. T. M. Yagüe,et al. Non-alcoholic fatty liver disease. From insulin resistance to mitochondrial dysfunction. , 2006 .
[101] G. Marchesini,et al. Metabolic syndrome and NASH. , 2007, Clinics in liver disease.
[102] C. Cotman,et al. Bax Protein Expression Is Increased in Alzheimer's Brain: Correlations with DNA Damage, Bcl‐2 Expression, and Brain Pathology , 1997, Journal of neuropathology and experimental neurology.
[103] C. Kahn,et al. Role for neuronal insulin resistance in neurodegenerative diseases , 2004 .
[104] M. Nöldner,et al. Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761) , 1999, Journal of Neural Transmission.
[105] Takafumi Saito,et al. 1. Fatty liver and non-alcoholic steatohepatitis. , 2007, Internal medicine.
[106] S. Craft. Insulin resistance and cognitive impairment: a view through the prism of epidemiology. , 2005, Archives of neurology.
[107] H. Fibiger,et al. Role of forebrain cholinergic systems in learning and memory: relevance to the cognitive deficits of aging and Alzheimer's dementia. , 1993, Progress in brain research.
[108] Suzanne Craft,et al. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. , 2007, Current Alzheimer research.
[109] Ming Tong,et al. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.
[110] J. Wands,et al. Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells , 2003, Cellular and Molecular Life Sciences CMLS.
[111] J. Woodgett,et al. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[112] M. Reger,et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. , 2008, Neurology.
[113] D. Puro,et al. Insulin-mediated regulation of neuronal maturation. , 1984, Science.
[114] M. Kearney,et al. The role of IGF‐I and its binding proteins in the development of type 2 diabetes and cardiovascular disease , 2008, Diabetes, obesity & metabolism.
[115] W. Markesbery,et al. Oxidative Alterations in Alzheimer's Disease , 1999, Brain pathology.
[116] G. Winocur,et al. Memory impairment in obese Zucker rats: an investigation of cognitive function in an animal model of insulin resistance and obesity. , 2005, Behavioral neuroscience.
[117] J. Wands,et al. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.
[118] K. Jellinger,et al. Synaptic pathology in alzheimer's disease: Immunological data for markers of synaptic and large dense-core vesicles , 1992, Neuroscience.
[119] B. Burgering,et al. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction , 1995, Nature.
[120] R. Nixon. The calpains in aging and aging-related diseases , 2003, Ageing Research Reviews.
[121] D. Leys,et al. Diabetes mellitus and dementia. , 2006, Diabetes & metabolism.
[122] S. Hoyer,et al. The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update , 2002, Journal of Neural Transmission.
[123] Jun-Li Liu,et al. Does IGF-I stimulate pancreatic islet cell growth? , 2007, Cell Biochemistry and Biophysics.
[124] I. Nishimoto,et al. Characterization of the toxic mechanism triggered by Alzheimer's amyloid‐β peptides via p75 neurotrophin receptor in neuronal hybrid cells , 2003, Journal of neuroscience research.
[125] N. Wilczak,et al. Insulin-like Growth Factor System Regulates Oligodendroglial Cell Behavior: Therapeutic Potential in CNS , 2008, Journal of Molecular Neuroscience.
[126] Ronald C Petersen,et al. Increased risk of type 2 diabetes in Alzheimer disease. , 2004, Diabetes.
[127] L. Launer. Diabetes and brain aging: Epidemiologic evidence , 2005, Current diabetes reports.
[128] Richard Mayeux,et al. Relation of diabetes to mild cognitive impairment. , 2007, Archives of neurology.
[129] L. Tafaro,et al. [Risk factors for cognitive impairment]. , 2004, Recenti progressi in medicina.
[130] D. Pessayre. Role of mitochondria in non‐alcoholic fatty liver disease , 2007, Journal of gastroenterology and hepatology.
[131] J. Wands,et al. Chronic gestational exposure to ethanol impairs insulin-stimulated survival and mitochondrial function in cerebellar neurons , 2002, Cellular and Molecular Life Sciences CMLS.
[132] A. Brun,et al. Synapse loss and gliosis in the molecular layer of the cerebral cortex in Alzheimer's disease and in frontal lobe degeneration. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[133] K. Yaffe,et al. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. , 2007, Current Alzheimer research.
[134] T Szkudelski,et al. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. , 2001, Physiological research.
[135] J. Wands,et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? , 2005, Journal of Alzheimer's disease : JAD.
[136] Jan Born,et al. Intranasal insulin improves memory in humans , 2004, Psychoneuroendocrinology.